Clinical Trial Update: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany [Phase 3]

View source ↗

Summary

Phase 3 multicenter trial evaluating whether lowering lipoprotein(a) with pelacarsen (TQJ230) reduces weekly lipoprotein(a) apheresis sessions in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Hyperlipoproteinemia

Drugs mentioned

• Pelacarsen (TQJ230) (pelacarsen)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hyperlipoproteinemia(a) | Phase 3 | Status: COMPLETED